Akari Therapeutics (AKTX) vs Shuttle Pharmaceuticals (SHPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Akari Therapeutics (AKTX) has outperformed Shuttle Pharmaceuticals (SHPH) over the past year, losing 60.1% versus a loss of 78.2%. Akari Therapeutics is the larger company by market cap ($16.7 million vs $16.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTX | SHPH |
|---|---|---|
| Share price | $7.18 | $3.49 |
| Market cap | $16.70M | $16.63M |
| 1-day change | +7.00% | -10.51% |
| YTD return | -37.89% | -80.61% |
| 1-year return | -60.11% | -78.19% |
| 5-year return | -99.47% | — |
| EPS (TTM) | $0.00 | $-16.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-17.30M | $-11.72M |
| 52-week high | $29.32 | $44.40 |
| 52-week low | $3.02 | $2.58 |
| Distance from 52-week high | -75.51% | -92.14% |
| Analyst consensus | none | — |
| Avg. price target upside | +255.15% | — |
| Average volume | 58.54K | 41.80K |
| Shares outstanding | 2.33M | 4.76M |
| Employees | 5 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AKTX has outperformed SHPH by 18.1 percentage points over the past year.
About Akari Therapeutics
AKTX stock →Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Shuttle Pharmaceuticals
SHPH stock →Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
AKTX vs SHPH FAQ
Which is bigger, Akari Therapeutics or Shuttle Pharmaceuticals?
Akari Therapeutics (AKTX) is larger, with a market capitalization of $16.70M compared with $16.63M for Shuttle Pharmaceuticals (SHPH).
Which stock has performed better over the past year, AKTX or SHPH?
AKTX returned -60.11% over the past 12 months, compared with -78.19% for SHPH (price return, excluding dividends). Past performance does not predict future results.
Are Akari Therapeutics and Shuttle Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.